ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

New Treatment For CML Could Be Model for Molecular Target-Based Therapeutics

December 10, 1999

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

December 3, 1993

Cancer Center In Russia Seeks Cancer Drugs, Other Supplies, From US

July 30, 1993

In brief: Cancer Investment “Drop In The Bucket,” OMB Is The “Second Greatest Kill,” Pepper Says

August 10, 1979

In Brief: Over Half Of Ovarian Cancer Patients Staged Incorrectly; Senate Gets Funding Resolution

April 12, 1985

Hollings Resolution Recognizes 20th Year Of National Cancer Act

May 3, 1991